Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-024-06945-x ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Kei Yaginuma und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. Hauptthemen laut MEDLINE: Astatine, Glutamate Carboxypeptidase II, Prostatic Neoplasms, Antigens, Surface. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: JSPS KAKENHI Grant, Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake, Japanese Urological Association Young Researcher Promotion Grant.
Abstract (Originalsprache)
PURPOSE: Prostate-specific membrane antigen (PSMA)-targeted alpha therapy is considered a promising alternative treatment for metastatic castration-resistant prostate cancer (mCRPC). Though astatine-211 (211At) is potentially useful alpha-emitter producible by cyclotrons, its clinical application has been limited by instability and a tendency to deastatination in vivo. To overcome these challenges, we developed [211At]At-NpG-PSMA, a novel PSMA ligand with a neopentyl-glycol structure that enhances in vivo stability against deastatination. This study aimed to evaluate the stability, anti-tumour effect, and safety of [211At]At-NpG-PSMA in mice. METHODS: Xenograft models were prepared by subcutaneous transplantation of PSMA-positive PC-3 PIP cells into BALB/c nu/nu mice. [211At]At-NpG-PSMA was administered to assess biodistribution, and the anti-tumour effect was evaluated at doses of 0.32, 1.00 and 1.93 MBq in comparison with saline. Histopathological examinations were performed to evaluate damage to normal organs. RESULTS: [211At]At-NpG-PSMA demonstrated high tumour uptake (42.0 ± 13.1%ID/g at 3 h) with minimal uptake in non-target tissues, including thyroid, stomach and salivary grands (0.28 ± 0.20%ID, 0.71 ± 0.12%ID/g and 0.88 ± 0.10%ID/g at 3 h, respectively). A dose-dependent anti-tumour effect was observed, with tumour volumes increasing by 796.0 ± 437.6% in the control versus 161.0 ± 213.4%, -76.4 ± 19.2% and - 59.5 ± 41.6% in the 0.32, 1.00 and 1.93 MBq groups, respectively, by day 15. Mild renal tubule regeneration was noted in the 1.00 MBq group. CONCLUSION: [211At]At-NpG-PSMA demonstrated significant stability in vivo and anti-tumour effects with minimal side effects, indicating its potential as a new therapeutic drug for PSMA-targeted alpha therapy in mCRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.
- Advanced Clinical Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
- Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan.
- Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
- Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan. ykojima@fmu.ac.jp.
Förderung
- JSPS KAKENHI Grant
- Fukushima reconstruction budget from the Japanese government in response to the Great East Japan Earthquake
- Japanese Urological Association Young Researcher Promotion Grant
- Kobayashi Foundation for Cancer Research
- Takeda Science Foundation
Zitieren
APA
Yaginuma, K., Takahashi, K., Hoshi, S., Joho, T., Shimoyama, S., Hasegawa, N., Hasegawa, K., Zhao, S., Ukon, N., Makabe, S., Meguro, S., Onagi, A., Matsuoka, K., Ogawa, S., Uemura, M., Yamashita, T., Suzuki, H., Uehara, T., & Kojima, Y. (2025). Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06945-x
Vancouver
Yaginuma K, Takahashi K, Hoshi S, Joho T, Shimoyama S, Hasegawa N, et al. Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-024-06945-x
BibTeX
@article{Yaginuma2025,
author = {Yaginuma, Kei and Takahashi, Kazuhiro and Hoshi, Seiji and Joho, Taiki and Shimoyama, Saki and Hasegawa, Naoko and Hasegawa, Koki and Zhao, Songji and Ukon, Naoyuki and Makabe, Syunta and Meguro, Satoru and Onagi, Akifumi and Matsuoka, Kanako and Ogawa, Soichiro and Uemura, Motohide and Yamashita, Tomoki and Suzuki, Hiroyuki and Uehara, Tomoya and Kojima, Yoshiyuki},
title = {Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-024-06945-x}
}
EUVIMED